RVL Pharmaceuticals plc
RVLPQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.26M | 8.83M | 9.81M | 10.02M | 8.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.26M | 8.83M | 9.81M | 10.02M | 8.45M |
| Cost of Revenue | 1.95M | 2.30M | -240.00K | 2.53M | 2.23M |
| Gross Profit | 6.31M | 6.53M | 10.05M | 7.50M | 6.22M |
| SG&A Expenses | 13.89M | 16.20M | 17.60M | 19.38M | 18.27M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.38M | 19.12M | 18.25M | 22.94M | 21.67M |
| Operating Income | -8.12M | -10.29M | -8.44M | -12.92M | -13.22M |
| Income Before Tax | -24.00M | -11.55M | -18.60M | -14.38M | -11.83M |
| Income Tax Expenses | -113.00K | 58.00K | -285.00K | 63.00K | 277.00K |
| Earnings from Continuing Operations | -23.89M | -11.61M | -18.32M | -14.45M | -12.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.89M | -11.61M | -18.32M | -14.45M | -12.11M |
| EBIT | -8.12M | -10.29M | -8.44M | -12.92M | -13.22M |
| EBITDA | -8.03M | -10.20M | -8.34M | -12.83M | -13.13M |
| EPS Basic | -0.24 | -0.12 | -0.18 | -0.16 | -0.14 |
| Normalized Basic EPS | -0.04 | -0.06 | 0.00 | -0.12 | -0.08 |
| EPS Diluted | -0.24 | -0.12 | -0.18 | -0.16 | -0.14 |
| Normalized Diluted EPS | -0.04 | -0.06 | 0.00 | -0.12 | -0.08 |
| Average Basic Shares Outstanding | 99.37M | 99.32M | 99.16M | 92.76M | 83.58M |
| Average Diluted Shares Outstanding | 99.37M | 99.32M | 99.16M | 92.76M | 83.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |